RACE-3研究正在进行：通过上游和下游治疗实现双重锁定窦性心律。 - Suppr

Suppr

超能文献

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.

作者信息

Pavlovic Davor, Kirchhof Paulus, Fabritz Larissa

机构信息

Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.

Sandwell and West Birmingham NHS Trust, Birmingham, UK.

出版信息

Eur Heart J. 2018 Aug 21;39(32):2997-2999. doi: 10.1093/eurheartj/ehy018.

DOI:10.1093/eurheartj/ehy018

PMID:29425294

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6110193/

Abstract

摘要

相似文献

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.RACE-3研究正在进行：通过上游和下游治疗实现双重锁定窦性心律。

Eur Heart J. 2018 Aug 21;39(32):2997-2999. doi: 10.1093/eurheartj/ehy018.

Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance.胺碘酮对持续性心房颤动的药物复律可预测长期窦性心律维持。

J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):179-86. doi: 10.1177/107424840300800302.

Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.胺碘酮用于直流电复律失败后慢性心房颤动患者窦性心律的恢复与维持。

Clin Cardiol. 1997 Apr;20(4):337-40. doi: 10.1002/clc.4960200407.

[Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study].胺碘酮与索他洛尔治疗心房颤动的效果：一项随机对照临床研究

Zhonghua Yi Xue Za Zhi. 2006 Jan 10;86(2):121-3.

Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]).索他洛尔与胺碘酮在维持心房颤动患者窦性心律稳定性方面的比较（索他洛尔 - 胺碘酮房颤疗效试验 [Safe - T]）

Am J Cardiol. 2003 Aug 15;92(4):468-72. doi: 10.1016/s0002-9149(03)00671-4.

Control of rate versus rhythm in rheumatic atrial fibrillation: a randomized study.风湿性心房颤动中率控制与节律控制的比较：一项随机研究。

Indian Heart J. 2004 Mar-Apr;56(2):110-6.

Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation.胺碘酮用于恢复心房颤动患者的窦性心律。

Card Electrophysiol Rev. 2003 Sep;7(3):297-9. doi: 10.1023/B:CEPR.0000012400.34597.00.

Amiodarone versus sotalol for atrial fibrillation.胺碘酮与索他洛尔治疗心房颤动的比较。

N Engl J Med. 2005 May 5;352(18):1861-72. doi: 10.1056/NEJMoa041705.

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.胺碘酮对心力衰竭合并心房颤动患者窦性心律的自发转复及维持作用：来自退伍军人事务部充血性心力衰竭抗心律失常治疗生存试验（CHF-STAT）的观察结果。退伍军人事务部CHF-STAT研究人员

Circulation. 1998 Dec 8;98(23):2574-9. doi: 10.1161/01.cir.98.23.2574.

Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation.心房颤动药物复律后左心房顿抑

Kardiol Pol. 2005 Sep;63(3):254-62; discussion 263-4.

引用本文的文献

Atrial fibrillation: villain or bystander in vascular brain injury.心房颤动：血管性脑损伤中的“反派”还是“旁观者”？

Eur Heart J Suppl. 2020 Dec 6;22(Suppl M):M51-M59. doi: 10.1093/eurheartj/suaa166. eCollection 2020 Nov.

Risk Factor Management in Atrial Fibrillation.心房颤动的危险因素管理

Arrhythm Electrophysiol Rev. 2018 Jun;7(2):118-127. doi: 10.15420/aer.2018.18.2.

本文引用的文献

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.针对潜在疾病的靶向治疗可改善持续性心房颤动患者的窦律维持：RACE 3 试验结果。

Eur Heart J. 2018 Aug 21;39(32):2987-2996. doi: 10.1093/eurheartj/ehx739.

PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.肺静脉隔离伴或不伴抗心律失常药物治疗复发性心房颤动患者（POWDER AF）：一项多中心随机试验的结果。

Eur Heart J. 2018 Apr 21;39(16):1429-1437. doi: 10.1093/eurheartj/ehx666.

European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers.欧洲心脏病学会为心房颤动患者及其医疗保健提供者提供的智能手机和平板电脑应用程序。

Europace. 2018 Feb 1;20(2):225-233. doi: 10.1093/europace/eux299.

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.探索心房高率发作患者的口服抗凝治疗：心房高率发作患者非维生素K拮抗剂口服抗凝剂（NOAH-AFNET 6）试验的原理与设计

Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.心房颤动心率控制综述以及RATE-AF试验的基本原理和方案。

BMJ Open. 2017 Jul 20;7(7):e015099. doi: 10.1136/bmjopen-2016-015099.

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.阿哌沙班用于降低器械检测到的亚临床房颤患者血栓栓塞事件（ARTESiA）试验的原理与设计

Am Heart J. 2017 Jul;189:137-145. doi: 10.1016/j.ahj.2017.04.008. Epub 2017 Apr 24.

The future of atrial fibrillation management: integrated care and stratified therapy.心房颤动管理的未来：综合护理和分层治疗。

Lancet. 2017 Oct 21;390(10105):1873-1887. doi: 10.1016/S0140-6736(17)31072-3. Epub 2017 Apr 28.

IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.螺内酯对射血分数保留的房颤患者心肌纤维化的影响及对运动耐量的改善：IMPRESS-AF随机对照试验的原理与设计

BMJ Open. 2016 Oct 5;6(10):e012241. doi: 10.1136/bmjopen-2016-012241.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。

Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.

Perioperative Rosuvastatin in Cardiac Surgery.心脏手术中的围手术期瑞舒伐他汀。

N Engl J Med. 2016 May 5;374(18):1744-53. doi: 10.1056/NEJMoa1507750.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验